{"entity":{"id":"nct05966194","kind":"trial","name":"RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer","aka":[],"tldr":"A phase 2 trial of Cisplatin in head and neck squamous cell carcinoma, run by EpicentRx, Inc., active and no longer recruiting.","summary":"RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer is a phase 2 interventional study registered as NCT05966194 by EpicentRx, Inc., with 216 participants enrolled, started 2024-04-02 and due to reach its primary completion in 2027-07-01. Interventions recorded: RRx-001, Intensity Modulated Radiation Therapy (IMRT) and Cisplatin for injection 100 mg/m2.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05966194","url":"https://clinicaltrials.gov/study/NCT05966194"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["cisplatin"],"companies":["epicentrx"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05966194","phase":"2","setting":"A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx","sponsor":"EpicentRx, Inc.","enrolled":216,"outcomes":[]},"route":"/trials/nct05966194/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"}],"company":[{"id":"epicentrx","kind":"company","name":"EpicentRx","route":"/companies/epicentrx/"}]}}